About Careers Internship MedBlog Contact us

Using Fewer Drugs may Be Best for Treating Malaria

by Medindia Content Team on November 27, 2007 at 3:46 PM
Using Fewer Drugs may Be Best for Treating Malaria

A recent study has revealed that the current dosage of drugs used in treating malaria may be helping the parasites become resistant to them instead of treating the disease.

According to the studies, the optimal use of the drugs might slow the spread of drug resistance while making the patient just as healthy. Andrew Read, professor of biology at Penn State, and an associate at the Center for Infectious Disease Dynamics said that normally in the absence of drugs, the susceptible pathogens keep the resistant ones from proliferating. But when infections are treated with drugs, the dynamic changes.


"Drugs kill off the susceptible parasites letting their competitors, the resistant ones, fill the vacant space and expand their numbers," Read said.

The study was conducted on mice infected with malaria to see how the parasites respond to drug treatment. Researchers found that once the drugs eliminated the susceptible microbes, the number of resistant bugs increased twice as much, compared to when the susceptible microbes were present, or when the infections comprised only resistant bugs.

"The more drugs you use, the worse you make the situation in terms of the evolution of drug resistance. This massively increases the rate of spread of resistance, so the drugs become less and less useful," he added.

The increase in parasite numbers was found to be directly proportionate to the duration of drug treatment. "Resistant parasites not only survive but do much better because the drugs have successfully removed their competitors," Read explained.

"We suspect this is what is causing the short lifespan of many antimalarial drugs," he added. If the infections in mice mirror malarial infections in humans, the findings may offer a promising solution in slowing the spread of such drug resistance.

The research team also included Andrew R. Wargo, now a post-doctoral researcher at the University of Washington, Seattle, Jacobus C. de Roode, now an assistant professor at Emory University, and Silvie Huijben and James Shephard, doctoral student and undergraduate student respectively at the University of Edinburgh.

The findings appear online in the Proceedings of the National Academy of Sciences.

Source: ANI
Font : A-A+



Recommended Readings

Latest Drug News

Promising ALS Drug Candidate Extends Lifespan
The study explores whether CDNF could influence the progression of ALS in rodent models and to elucidate the mechanism through which it operates.
Amoxicillin-Calvulanate Vs Amoxicillin Preference in Child Sinusitis Treatment
Amoxicillin-clavulanate use in acute sinusitis patients is associated with a higher incidence of adverse events.
ADHD Medication Errors Surge by Nearly 300%
Professionals advocate for enhanced education of patients and caregivers, and creation of more effective child-resistant systems for monitoring ADHD medication.
Unknown Medication Side Effects Reported by 52% of Indian Families
In June, WHO raised concerns about 7 Indian cough syrups after complaints from several countries about contamination and health issues.
Painkillers With Hormonal Contraception Linked to Blood Clot Risk
Women using hormonal contraception, along with their healthcare providers, should explore alternative pain relief options instead of NSAIDs.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
Greetings! How can I assist you?MediBot

Using Fewer Drugs may Be Best for Treating Malaria Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests